Fred Meyer, Phd, Cfa Email & Phone Number

Newton, MA, US

Kansas City, KS, US

The Institute for Advancing Medical Innovation (IAMI) translates laboratory discoveries into drugs, diagnostics and medical devices. IAMI's focus is cancer, neurologic and rare diseases. Using industry best practices, project plans are developed and executed resulting in development of data packages necessary to validate commercial opportunities..

Lawrence, KS, US

Medical device company dedicated to improving the lives of patients who suffer from spine and orthopedic diseases via a patient-powered smart spinal fusion device with Breakthrough Device Designation by the US Food and Drug Administration.

Discovering novel agents to treat cholangiocarcinoma

Developing Factor XIa inhibitors for the prevention of stroke and thrombosis.

Assist early to mid stage ventures with valuation and positioning to present compelling partnering and investment opportunities. Entrepreneurial and creative approach to developing ventures to maximize value.

Palm Beach Gardens, Florida, US

Xcovery’s lead candidate, X-396, is a potent small molecule anaplastic lymphoma kinase (ALK) inhibitor for the treatment of NSCLC where ALK is deregulated. X-396 is up to 10 times more potent than competitive ALK inhibitors and is currently in Phase 2 clinical trials. Importantly, X-396 has shown activity in some ALK mutations that confer resistance to.

Developing X-82, an orally-administered targeted treatment for wet AMD and solid tumors. Currently in Phase 2 clinical trials, X-82 inhibits both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Preliminary data have shown that orally administered X-82 may provide an alternative delivery option to.

Creating and financing companies to initiate early pharmaceutical clinical development

Joint venture with Capstone Therapeutics (OTCQB: CAPS) to develop Apo E peptide mimetics for refractory hyperlipidemias and acute coronary syndrome

Collaboration with clients to efficiently develop novel early-stage therapeutics in virtual companies from venture creation through clinical proof-of-concept. Operating and deal-making experience used to match entrepreneurs, corporate partners, researchers, contract research organizations, and investors.

Los Angeles, CA, US

Worked with NIH-CAP SBIR ventures to commercialize their technologies

Design and finance of licensing partnerships and spin-outs for diverse healthcare clients with drugs in development, discovery platform technologies, and medical devices, including creation of Artisan Pharma with $39m fundraise, based on licensing Western rights to Asahi Kasei’s late stage sepsis drug. Expertise in strategy formulation and valuation work.

New York, New York, US

Equity research covering companies with technology for rapid discovery and development of drug pipelines, including Abgenix, Alkermes, Alteon, Aradigm, Gilead, Human Genome Sciences, Inhale, Millennium, MedImmune, Tularik, Vertex, ViroPharma, and Vitex.

Boston, MA, US

Business development for three international portfolio companies.

Phd, Molecular Genetics

Bs With Honors, Genetics & Development